Universität zu Köln

von Tresckow, Bastian and Engert, Andreas (2013). Refractory Hodgkin Lymphoma. Curr. Opin. Oncol., 25 (5). S. 463 - 470. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. ISSN 1531-703X

Full text not available from this repository.

Abstract

Purpose of reviewDespite the advances in the treatment of Hodgkin Lymphoma, patients with refractory disease still have a poor prognosis. Hodgkin Lymphoma can be refractory at first diagnosis or might become refractory later in the course of treatment. Both situations represent a therapeutic challenge.Recent findingsIntensified chemotherapy with BEACOPP escalated has been evaluated in early unfavourable and advanced Hodgkin Lymphoma and led to an improved tumour control and reduced rates of refractory disease. Furthermore, there is growing evidence for the role of tandem autologous transplant in breaking refractory disease. For patients relapsing after autologous transplant, more recent analyses have reported outcome and defined risk factors. The antibody drug conjugate brentuximab vedotin is a new, highly effective therapeutic option for these patients. Dose-reduced allogeneic transplant is a therapeutic alternative for patients relapsing after autologous transplant, but induction of a remission is the prerequisite for a successful allogeneic transplant. Brentuximab vedotin has been evaluated as a bridge to allogeneic transplant for patients refractory to conventional treatment.SummaryRecent therapeutic advances have improved the prognosis of Hodgkin Lymphoma by prevention or successful treatment of refractory disease. The use of new drugs such as brentuximab vedotin will hopefully further increase the cure rates.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code von Tresckow, Bastian UNSPECIFIED UNSPECIFIED UNSPECIFIED Engert, Andreas UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-476345
DOI:	10.1097/01.cco.0000432524.62475.60
Journal or Publication Title:	Curr. Opin. Oncol.
Volume:	25
Number:	5
Page Range:	S. 463 - 470
Date:	2013
Publisher:	LIPPINCOTT WILLIAMS & WILKINS
Place of Publication:	PHILADELPHIA
ISSN:	1531-703X
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language STEM-CELL TRANSPLANTATION; HIGH-DOSE CHEMORADIOTHERAPY; BRENTUXIMAB VEDOTIN; PHASE-II; 1ST RELAPSE; DISEASE; TRIAL; INTENSITY; CHEMOTHERAPY; MULTICENTER Multiple languages Oncology Multiple languages
URI:	http://kups.ub.uni-koeln.de/id/eprint/47634